TRACON Pharmaceuticals, Inc. (TCON)
| Market Cap | 154.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.40M |
| Shares Out | 10.51M |
| EPS (ttm) | -2.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $10.61 |
| Previous Close | $10.14 |
| Change ($) | 0.47 |
| Change (%) | 4.64% |
| Day's Open | 10.05 |
| Day's Range | 10.05 - 10.77 |
| Day's Volume | 310,582 |
| 52-Week Range | 1.09 - 11.70 |
NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submit...
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...
NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Co...
SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...
SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...
Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal...
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020 TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subty...
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targ...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targ...
SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S. Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S.
TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S. Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S.
Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled in TRACON’s Pivotal ENVASARC Trial of Envafolimab as a Single Agent and in Combination with Yervoy
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...
Company Reaches Agreement with Regulatory Agency on Key Elements of ENVASARC Trial
TRACON seeks licensing partner to develop and commercialize TRC253 in China TRACON seeks licensing partner to develop and commercialize TRC253 in China
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
SAN DIEGO, March 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
OSAKA, Japan and SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San ...
TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q4 2019 Results - Earnings Call Transcript
SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
Shares of Tracon Pharmaceuticals Inc. TCON, -4.23% were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational ...
Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q3 2019 Results - Earnings Call Transcript
SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...
TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q2 2019 Results - Earnings Call Transcript
Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON) were rallying Thursday.
TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q1 2019 Results - Earnings Call Transcript
TRACON Pharmaceuticals Inc (NASDAQ: TCON), a thinly traded nanocap biotech, is plunging Friday after it announced shelving of a study of a pipeline asset.
Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the company said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent...
About TCON
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for... [Read more...]
| Industry Biotechnology | IPO Date Jan 30, 2015 |
| CEO Dr. Charles P. Theuer | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol TCON |
Analyst Forecasts
According to 4 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 9.17, which is a decrease of -13.57% from the latest price.